152 related articles for article (PubMed ID: 34080947)
1. Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
Rodrigues JM; Porwit A; Hassan M; Ek S; Jerkeman M
Leuk Lymphoma; 2021 Nov; 62(11):2637-2647. PubMed ID: 34080947
[TBL] [Abstract][Full Text] [Related]
2. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
[TBL] [Abstract][Full Text] [Related]
4. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
[TBL] [Abstract][Full Text] [Related]
5. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
Ahmed M; Zhang L; Nomie K; Lam L; Wang M
Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
[TBL] [Abstract][Full Text] [Related]
6. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
[TBL] [Abstract][Full Text] [Related]
7. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.
Zhang J; Jima D; Moffitt AB; Liu Q; Czader M; Hsi ED; Fedoriw Y; Dunphy CH; Richards KL; Gill JI; Sun Z; Love C; Scotland P; Lock E; Levy S; Hsu DS; Dunson D; Dave SS
Blood; 2014 May; 123(19):2988-96. PubMed ID: 24682267
[TBL] [Abstract][Full Text] [Related]
8. Genomic landscape and prognostic analysis of mantle cell lymphoma.
Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
[TBL] [Abstract][Full Text] [Related]
9. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.
Hansen MH; Cédile O; Blum MK; Hansen SV; Ebbesen LH; Bentzen HHN; Thomassen M; Kruse TA; Kavan S; Kjeldsen E; Kristensen TK; Haaber J; Abildgaard N; Nyvold CG
Exp Hematol; 2020 Apr; 84():7-18.e12. PubMed ID: 32173361
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
12. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
13. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
Karolová J; Kazantsev D; Svatoň M; Tušková L; Forsterová K; Maláriková D; Benešová K; Heizer T; Dolníková A; Klánová M; Winkovska L; Svobodová K; Hojný J; Krkavcová E; Froňková E; Zemanová Z; Trněný M; Klener P
Am J Hematol; 2023 Oct; 98(10):1627-1636. PubMed ID: 37605345
[TBL] [Abstract][Full Text] [Related]
14. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.
Pararajalingam P; Coyle KM; Arthur SE; Thomas N; Alcaide M; Meissner B; Boyle M; Qureshi Q; Grande BM; Rushton C; Slack GW; Mungall AJ; Tam CS; Agarwal R; Dawson SJ; Lenz G; Balasubramanian S; Gascoyne RD; Steidl C; Connors J; Villa D; Audas TE; Marra MA; Johnson NA; Scott DW; Morin RD
Blood; 2020 Jul; 136(5):572-584. PubMed ID: 32160292
[TBL] [Abstract][Full Text] [Related]
15. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
16. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Che Y; Liu Y; Yao Y; Hill HA; Li Y; Cai Q; Yan F; Jain P; Wang W; Rui L; Wang M
Blood Cancer J; 2023 Feb; 13(1):27. PubMed ID: 36797243
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
[TBL] [Abstract][Full Text] [Related]
18. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.
Hartmann E; Fernàndez V; Moreno V; Valls J; Hernández L; Bosch F; Abrisqueta P; Klapper W; Dreyling M; Hoster E; Müller-Hermelink HK; Ott G; Rosenwald A; Campo E
J Clin Oncol; 2008 Oct; 26(30):4966-72. PubMed ID: 18606985
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling and management of mantle cell lymphoma.
Ruan J
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
